Drugs / pegylated carboxyhemoglobin bovine
pegylated carboxyhemoglobin bovine
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04677777 | Apr 2024 → Feb 2025 | ischemic stroke | Prolong Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02754999 | Mar 2016 → May 2017 | anemia | Prolong Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02437422 | Jun → Nov 2015 | chronic kidney disease | Prolong Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01848925 | May 2013 → Jul 2014 | sickle cell disease | Prolong Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01847222 | May 2013 → May 2014 | — | Prolong Pharmaceuticals | Terminated | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT02411708 | Nov 2016 → Dec 2017 | sickle cell disease | Prolong Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02672540 | Jul 2016 → May 2017 | sickle cell disease | Prolong Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02600390 | Mar → Oct 2016 | ulcer of lower limbs | Prolong Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02658162 | Feb 2016 → Oct 2018 | disease related to solid organ transplantation | Prolong Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT02323685 | Dec 2014 → Jun 2016 | brain ischemia | Prolong Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02490202 | Aug 2015 → Aug 2016 | disease related to solid organ transplantation | Prolong Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pegylated carboxyhemoglobin bovine | “SANGUINATE (pegylated carboxyhemoglobin bovine)” NCT02600390 ↗ |
| Known as | PP-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04677777 ↗ |
| Known as | SANGUINATE | “SANGUINATE™ in Sickle Cell Disease Associated Leg Ulcer” NCT02600390 ↗ |
| Modality | Protein / enzyme biologic | “Single infusion of SANGUINATE (pegylated carboxyhemogloblin)” NCT02323685 ↗ |
| Route | Intravenous | “40 mg/mL intravenous infusion.” NCT01848925 ↗ |